5414x < 2027 >
: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update
The full text and detailed report of this "paper" (regulatory announcement) include the following key sections and financial highlights: : Established a strategic collaboration with Cepheid (a
: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth : driven by AMR and EMEAI growth.
: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year. : Established a strategic collaboration with Cepheid (a
: £13.0 million (+52.9%), driven by AMR and EMEAI growth.
: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update
The full text and detailed report of this "paper" (regulatory announcement) include the following key sections and financial highlights:
: 58.2%, slightly down from 58.8% in H1 2024 due to one-off inventory charges and currency headwinds, despite an underlying improvement of 525 basis points. Segment Growth :
: £72.1 million, a 22.1% increase compared to H1 2024 (£59.0 million). Gross Profit : £61.4 million, up 24% year-on-year.
: £13.0 million (+52.9%), driven by AMR and EMEAI growth.